Resistant Bacteria in Children in France

The main of this study is to evaluate the relevance of prescribing "new antibiotics" according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation

As this is a surveillance study, the clinical and biological characteristics of the children included will be described.

Inclusion criteria

• Children under 18 years of age
• Hospitalized in France in a hospital center working with the ACTIV/GPIP network
• Treated with one or more of the following antibiotics:

• Colimycin (Colistimethate sodium)
• Cefiderocol
• Aztreonam in combination
• Ceftolozane-Tazobactam
• Ceftazidime-avibactam
• Meropenem/vaborbactam
• Imipenem/Relebactam
• Tigecycline
• Daptomycin
• Ceftaroline fosamil
• Tedizolid phosphate
• Fidaxomicin
• Ceftobiprole
• Dalbavancin

In association with a documented infection performed by:

• Blood culture
• Normally sterile site

• Cerebrospinal fluid
• Pleural fluid
• Pleura
• Peritoneum
• Joint fluid
• Other
• Urine sampling if the bacteria was considered responsible for the infection (associated with a leukocyturia ≥10,0000)
• Respiratory specimens if the bacteria was considered responsible for the infection
• Sampling on material such as:Intubation probe, Orthopedic, Urological, Central Nervous System (CNS),....

• Related to colonization with multidrug-resistant bacteria without documentation.

Exclusion criteria

• Refusal of participation by the patient or his/her parent
• Medical history of mucoviscidosis